Abstract OT1-13-01: MammaPrint, BluePrint, and full-genome data linked with clinical data to evaluate new gene expression profiles (FLEX)

Ongoing Clinical Trials Pub Date : 2019-02-15 DOI:10.1158/1538-7445.sabcs18-ot1-13-01

A. Brufsky, J. Crozier, I. Grady, T. Lomis, P. Whitworth, E. Rehmus, G. Srkalović, Ll Lee, P. Blumencranz, P. Baron, B. Mavromatis, S. Untch, L. Blumencranz, E. Yoder, W. Audeh

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

OT1-13-01:将MammaPrint、BluePrint和全基因组数据与临床数据联系起来，评估新的基因表达谱(FLEX)

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Ongoing Clinical Trials

自引率

0.00%

发文量

期刊最新文献

Abstract OT3-07-01: Efficacy of magnetic resonance-guided high intensity focused ultrasound for the ablation of breast cancer Abstract OT2-03-04: A trial of induction Talazoparib followed by a combination of Talazoparib and Avelumab in advanced breast cancer: The TALAVE study Abstract OT2-04-04: Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase 2 trial Abstract OT1-04-02: POSITIVE: A study evaluating pregnancy, disease outcome and safety of interrupting endocrine therapy for premenopausal women with endocrine responsive breast cancer who desire pregnancy (IBCSG 48-14/big 8-13) Abstract OT1-03-01: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 in combination with alpelisib (BYL719) in estrogen receptor-positive (ER+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with progression on endocrine thera